Netherlands-based medical robotics company Vitestro has signed an agreement with a healthcare provider OLVG Lab for the supply of its multiple autonomous blood-drawing devices.
The autonomous blood-drawing devices are expected to be delivered to OLVG Lab upon receiving CE mark approval in Europe.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Designed to support consistent blood drawing, the devices are expected to address the growing shortage of healthcare workers.
OLVG Lab director Anja Leyte said: “Vitestro’s technology will improve the standardisation and optimisation of the sampling procedure and it helps solve staff shortages in our blood-drawing department.
“But more importantly, the patients are also very positive. Our staff are really enthusiastic as well and can’t wait to start using this breakthrough technology in our healthcare.”
Since 2018, OLVG Lab has been engaged in the development of autonomous blood-drawing devices.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBoth patients and blood-drawing staff at OLVG hospital were assessed with Vitestro’s technology.
Multiple hospitals, laboratories and blood-drawing departments are also planning to use the company’s blood-drawing technology. The delivery of the devices is anticipated to begin in late 2024.
Vitestro co-founder and CEO Toon Overbeeke said: “After more than 5 years of co-creation and development with OLVG Lab, this is a special moment.
“It is a privilege to be the first to place our innovation at OLVG Lab. Together, we will make sure this innovation will become a great success for both employees and patients.”
